CND Life Sciences announced that its Syn-One® biomarker services were utilized in a Phase 2 clinical trial conducted by ABLi Therapeutics for its Parkinson’s disease candidate risvodetinib. According to the company, the services enabled measurement of phosphorylated α-synuclein (P-SYN) deposition in cutaneous nerves, representing a novel exploratory endpoint for tracking synucleinopathy-related changes.
The company said the analysis involved 36 consenting subjects from the trial’s “201 Trial,” where skin biopsy samples from baseline to 12 weeks were assessed using the Syn-One Research Test in conjunction with its AI-assisted NerValence™ digital pathology tool. According to CND, the data showed a measurable reduction in P-SYN in treated participants, marking the first time such a biomarker change has been observed in a Parkinson’s drug trial.
CND claims that this application of its Syn-One services supports the potential role of peripheral nerve-based biomarkers in monitoring disease-modifying therapies for Parkinson’s and other synucleinopathies. The company said it will continue studies using the Syn-One platform, including an 18-month “Syn-Q” observational study supported by the Michael J. Fox Foundation, to further validate the technology’s utility in tracking disease progression and treatment response.
According to CND, the commercial test (Syn-One Test®) operates from its CLIA-certified and CAP-accredited laboratory, providing neurologists with a minimally invasive diagnostic tool for synuclein-driven disorders. The company said the partnership with ABLi underscores growing interest in leveraging cutaneous biopsy biomarkers in neurodegenerative clinical trials.
